Clinical Report: Real-World nAMD Treatment Patterns Reveal Cost of Switching
Overview
Revise to specify the implications of treatment patterns and potential cost savings more clearly.
Background
Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults, making effective and cost-efficient treatment critical. The choice of anti-VEGF therapy can significantly impact both patient outcomes and healthcare expenditures. Understanding real-world treatment patterns is essential for optimizing care and managing costs in this patient population.
Data Highlights
| Metric | Value |
|---|---|
| Patients starting with bevacizumab | 54% |
| Patients switching from bevacizumab within 1 year | 26% |
| 3-year cost of care with bevacizumab | $700 |
| 3-year cost of care after switching | $20,000 |
| Patients switching to aflibercept | 40% |
Key Findings
- 54% of nAMD patients began treatment with bevacizumab.
- 26% of patients switched to another anti-VEGF agent within one year of starting bevacizumab.
- The average 3-year cost of treating with bevacizumab is approximately $700, compared to $20,000 after switching.
- In a Medicare Advantage cohort, 70% started with bevacizumab, with over half switching, primarily to aflibercept.
- Concerns about the quality of compounded bevacizumab may contribute to high switch rates.
Clinical Implications
Healthcare providers should be aware of the financial implications associated with switching anti-VEGF therapies in nAMD patients. Maintaining patients on lower-cost treatments like bevacizumab may lead to significant cost savings, although quality concerns may necessitate switches. Ongoing evaluation of treatment efficacy and patient adherence is crucial.
Conclusion
The study underscores the need for careful consideration of treatment initiation and switching patterns in nAMD to manage costs effectively. Further investigation into the reasons for switching may help optimize treatment strategies.
References
- Vora RA, Retinal Physician, 2025 -- Real-World nAMD Treatment Patterns Reveal Cost of Switching
- Drugs - Real World Outcomes — Analysis of Treatment Trends, Relapse Rates, Resource Utilization, and Costs in Multiple Sclerosis Patients Transitioning to Second-Line Disease-Modifying Therapies: A Retrospective Claims Study
- Retinal Physician — Anti-VEGF Therapy & AMD Recommendations
- Drugs - Real World Outcomes — Impact of Esketamine Nasal Spray and Standard Treatments on Mental Health-Related Disability Days and Costs in Patients with Treatment-Resistant Depression in the United States
- Drugs - Real World Outcomes — Cost Trends Over Four Years in Real-World Patients Compared to Metabolic Profiles of Clinical Trial Participants Before and After Phentermine-Topiramate Treatment
- Age-Related Macular Degeneration Preferred Practice Pattern®
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab
- Real-World nAMD Treatment Patterns Reveal Cost of Switching | Retinal Physician
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.